Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320588 · ClinicalTrials.gov registry record · Phase 1
A Study in Patients With Advanced Cancers
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by BiOneCure Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
- 3
- Study locations
NCT05320588 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by BiOneCure Therapeutics. The registered enrollment target is 332 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05320588, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by BiOneCure Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
- 3
- Study locations
Study Summary
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BIO-106
Study Locations (3)
Texas
- NEXT Oncology Austin - Austin
- University of Texas MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05320588
The ClinicalTrials.gov registry entry for NCT05320588 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The listed sponsor is BiOneCure Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05320588 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05320588 about?
NCT05320588 is a clinical study titled "A Study in Patients With Advanced Cancers". A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
What is the current status of trial NCT05320588?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2022-03-25. Estimated completion is 2027-04.
What conditions does trial NCT05320588 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Advanced Cancer, Oncology.
What interventions are being tested in trial NCT05320588?
The interventions under investigation include: Pembrolizumab (DRUG), BIO-106 (DRUG).
Who is sponsoring clinical trial NCT05320588?
This trial is sponsored by BiOneCure Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05320588 being conducted?
This trial has 3 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.